[{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ European Innovation Council","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ European Innovation Council"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AC-0027838","moa":"TRKA receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACD440","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ACD440","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ACD440","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ACD440","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ACD440","moa":"TRPV1","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AC-0027875","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AC-0027875","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ACD137","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ACD137","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ACD680","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlzeCure Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AlzeCure Pharma \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by AlzeCure Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
